Home » Healthcare » Autologous Cell Therapy Market

Autologous Cell Therapy Market By Cell Type (Mesenchymal Stem Cells, Chondrocytes, Dendritic Cells, Tumor-Infiltrating Lymphocytes, Others) By Application (Cancer Treatment, Autoimmune Diseases, Cardiovascular Diseases, Musculoskeletal Disorders, Neurological Disorders, Others) – Growth, Share, Opportunities & Competitive Analysis, 2018 – 2028

Price: $4999

Published: | Report ID: 22007 | Report Format : PDF

Market Insights

  • The global demand for autologous cell therapy was valued at USD 4518.9 Million in 2022 and is expected to reach USD 22617.48 Million in 2030, growing at a CAGR of 22.3% between 2023 and 2030.
  • The mesenchymal stem cells segment is the market leader by cell type, accounting for more than 30% of total value in 2022, while the tumor-infiltrating lymphocytes segment is estimated to grow rapidly over the projection period.
  • The cancer treatment application category is expected to expand rapidly in the forecast period, while the autoimmune diseases segment has the highest market share in 2022.
  • The bone marrow source segment leads the global need for autologous cell therapy, accounting for more than 34% in 2022 and is predicted to expand at a high CAGR.
  • The hospitals and clinics category dominated the market with 40% of the total revenue share by end-user. In contrast, the research institutes category will expand fastest over the projected time frame.
  • North America is driving the rapid growth of the autologous cell therapy industry and accounted for more than one-third of the market in 2022, while Asia Pacific and Europe account for just under 54% of the market in 2022. In 2022, Europe had a market revenue share of more than 20%.
  • Autologous cell therapies are being explored for various therapeutic applications, including cancer treatment, cardiovascular diseases, neurological disorders, and autoimmune diseases.
  • The global autologous cell therapy market has been experiencing speedy growth in recent years, driven by advancements in regenerative medicine and cell therapy technologies.
  • Autologous cell therapies are gaining traction in treating rare diseases, where personalized approaches can offer hope for patients with limited treatment options.

Executive Summary

Market Definition

The autologous cell therapy market encompasses the healthcare sector dedicated to developing, producing, and commercializing therapeutic approaches that employ a patient’s cells, tissues, or biological materials for medical interventions. These innovative therapies involve collecting cells from the patient, their subsequent processing and modification outside the body, and the re-administration of these personalized treatments back to the same patient. Autologous cell therapies are employed to treat a diverse range of medical conditions, often capitalizing on the regenerative or immune-modulating properties of the patient’s cells, promising tailored and potentially more effective treatments while minimizing the risk of immune rejection.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

CTA Design Element 3

Market Overview

The global autologous cell therapy market has witnessed rapid growth in recent years and is expected to grow at a CAGR of 22.3% between 2023 and 2030. The market was valued at USD 4518.9 million in 2022 and is expected to reach USD 22617.48 million in 2030.

Autologous cell therapy is a unique treatment strategy that uses an individual’s cells cultivated and expanded outside the patient’s body before being reintroduced into the donor. It entails collecting, separating, and manipulating cells from the patient’s body, generally from blood, bone marrow, or adipose tissue. This personalized treatment strategy has various advantages, including a lower chance of immunological rejection or unpleasant responses because the cells are genetically matched to the patient.

The autologous cell therapy market is expanding rapidly, owing to rising awareness of personalized medical treatments, advances in regenerative medicine, and expanding applications in various medical disciplines. This market is seeing large investments in research & development, contributing to the launch of novel therapies and technologies. The increased frequency of chronic diseases and the possibility for improved patient outcomes drive global demand for autologous cell therapies.

Segmentation by Cell Type

  • The tumor-infiltrating lymphocytes (TILs) segment will exhibit the highest CAGR in the forecasted period. This upsurge can be attributed to the growing significance of TILs in cancer immunotherapy, particularly in treating melanoma and other solid tumors.
  • The mesenchymal stem cells (MSCs) segment currently leads the market share, holding over 30% in 2022. MSCs, known for their regenerative potential and immunomodulatory properties, continue to dominate the market, with applications from orthopedic conditions to autoimmune diseases.

Segmentation by Application

  • The autoimmune diseases segment is anticipated to achieve the highest CAGR over the projected period, driven by the growing prevalence of autoimmune disorders and the potential of autologous cell therapies in modulating the immune system.
  • The cancer treatment segment is leading the market share with over 28% in 2022, underlining the substantial adoption of autologous cell therapies, particularly CAR-T cell therapies, in oncology.

Segmentation by Source

  • The bone marrow segment remains dominant, satisfying more than 34% of the global demand for autologous cell therapy in 2022, with strong growth expectations. Bone marrow remains a rich source of various stem cells crucial for regenerative medicine.
  • The adipose tissue segment offers an alternative source to ensure comprehensive coverage addressing the remaining therapeutic needs, with its accessibility and potential for diverse cell types.

Segmentation by End-User

  • The research institutes segment is projected to witness the highest CAGR in the coming years, reflecting the importance of ongoing research and development efforts in advancing autologous cell therapy technologies and applications.
  • The hospitals and clinics segment currently leads the global market share, holding over 40% in 2022, signifying the increasing clinical adoption of autologous cell therapies in mainstream healthcare.

Segmentation by Region

  • North America stands out as a notably profitable region for industry players, accounting for over one-third of the share in 2022. A combination of advanced healthcare infrastructure, robust research initiatives, and a high prevalence of chronic diseases drives a strong regional market presence.
  • Europe and Asia Pacific collectively contributed under 54% share in 2022. With over 20% share, Europe demonstrates a robust market presence due to its developed healthcare systems and significant investments in cell therapy research and development.
  • The rest of the world, including Latin America, the Middle East, and Africa, fulfills the remaining demand for autologous cell therapy, with potential for growth as healthcare infrastructure and awareness continue to improve in these regions.

The increasing usage of such therapies in numerous industries like healthcare, regenerative medicine, and personalized medicine, as well as the rising need for innovative and effective treatment choices, are the primary drivers of growth in the global autologous cell therapy market.

In 2022, North America held the majority of the revenue share of the global autologous cell therapy market. The area benefits from a strong regulatory environment and healthcare infrastructure that encourage the creation and marketing of cutting-edge medical therapies. In addition, North America has been at the forefront of research and innovation in autologous cell therapy, with numerous academic institutions, biotechnology companies, and pharmaceutical firms actively engaged in research and clinical trials. The high prevalence of diseases such as cancer and cardiovascular disorders, coupled with a robust healthcare reimbursement system, has driven the adoption of autologous cell therapies in the region. For instance, the American Cancer Society’s 2022 report predicts that approximately 1.9 million new cancer cases will be identified in the United States. Also, 80% of patients diagnosed with cancer in the US are 55 or older, and 57% are 65 or older.

Over the projection period, Asia Pacific is expected to be the fastest-growing region. The region features a rapidly expanding healthcare sector, with increasing investments in R&D and growing awareness of personalized medicine. Moreover, Asia Pacific has a large and diverse patient population, providing a substantial pool of potential candidates for autologous cell therapies. The favorable regional regulatory environment, improving healthcare infrastructure, and comparatively lower treatment costs attract local and international players, driving innovation and market expansion. The prevalence of certain diseases, such as cancer and diabetes, is rising in the region, further fueling the demand for advanced and personalized treatment options and positioning the region as a key growth hub in the autologous cell therapy market.

Key Highlights of the Report

The global autologous cell therapy market is segmented by cell type, application, end-user, source, and region. Mesenchymal stem cells are currently the dominant cell type, showcasing their versatility and regenerative potential. At the same time, the tumor-infiltrating lymphocytes segment is poised for remarkable growth, particularly within the context of immunotherapy applications. Cancer treatment, focusing on CAR-T cell therapies, leads the market in terms of application, underscoring the pivotal role of autologous cell therapies in oncology. Simultaneously, autoimmune diseases are projected to witness the highest growth, aligning with the need for immune modulation in treating autoimmune disorders. Bone marrow remains the primary source for autologous cell therapies, owing to its rich reservoir of hematopoietic stem cells and multipotent stromal cells. Hospitals and clinics currently serve as the dominant end-users, reflecting the increasing clinical adoption of autologous cell therapies.

The trend towards personalized medicines and targeted therapies has increased market demand for autologous cell therapy. This method improves treatment outcomes by utilizing a patient’s cells, reducing the chance of rejection and increasing therapy efficacy. Technological advances in cell isolation, development and delivery techniques have dramatically enhanced the viability and scalability of autologous cell therapies. These improvements have enabled streamlined and standardized production procedures, making autologous cell therapies more accessible and cost-effective. The growing cases of chronic diseases such as cardiovascular disease, cancer, and autoimmune ailments has increased the need for novel therapeutic alternatives. Autologous cell therapies can also provide an upgraded response by utilizing the regenerative capacity of a patient’s cells. However, factors such as higher treatment costs, complex manufacturing processes, and regulatory limitations can hinder the widespread adoption of these therapies. The limited availability of skilled professionals and specialized facilities for cell-based therapies also impedes market growth.

The North American region leads the global autologous cell therapy market, owing to the widespread use of cutting-edge healthcare technology. The United States, in particular, is a prominent contributor to regional market growth due to its highly advanced healthcare infrastructure and rising demand for personalized cell-based treatments. On the other hand, the Asia-Pacific is experiencing rapid growth in the autologous cell therapy industry, attributed to the increasing adoption of cell-based therapies in healthcare. The large regional population and the high prevalence of chronic diseases present significant opportunities for autologous cell therapy, specifically in countries like India, Japan, China, and South Korea.

What Are The Main Drivers Of The Global Autologous Cell Therapy Market?

The primary drivers of the global autologous cell therapy market include the growing demand for personalized medicine, particularly in the treatment of cancer and other complex diseases, as autologous cell therapies offer tailored solutions that align with an individual’s genetic profile. Additionally, advancements in cell therapy technologies, such as CAR-T cell therapies, expanded applications of stem cells, and improved manufacturing processes, are expanding the market’s potential. Increasing research and development investments, favorable regulatory initiatives, and rising patient awareness propel the market forward. Moreover, the continuous exploration of autologous cell therapies for a broader spectrum of medical conditions, including rare diseases and degenerative disorders, is expected to sustain the market’s robust growth in the forecast period.

What Are The Major Challenges Faced By The Global Autologous Cell Therapy Market?

The global autologous cell therapy market encounters several significant challenges, including regulatory complexities surrounding the approval and manufacturing of personalized cell therapies, which can impede market expansion. Cost barriers associated with the intricate and often labor-intensive process of isolating and manufacturing patient-specific cells remain substantial, affecting accessibility and affordability. Besides, ensuring consistent quality control and standardization of production processes pose ongoing challenges, as does the need to address logistics and supply chain complexities, particularly for the timely and safe transportation of patient-derived cells. Market access issues stemming from variability in reimbursement policies across regions also impact the market, potentially limiting patient access to these innovative treatments.

What Are The Growth Opportunities In The Global Autologous Cell Therapy Market?

The global autologous cell therapy market presents promising growth opportunities driven by the increasing recognition of the potential of personalized medicine. Expanded applications beyond oncology, such as autoimmune diseases, cardiovascular disorders, and neurodegenerative conditions, offer a broader patient base and market reach. Advances in manufacturing technologies, like automation and scale-up capabilities, are poised to reduce production costs and improve the commercial viability of autologous cell therapies. Moreover, collaborations and partnerships among biotechnology firms, academic institutions, and healthcare providers fuel innovation and accelerate the development and commercialization of these therapies. The ongoing exploration of novel cell sources and innovative delivery methods also opens new therapeutic avenues, reaffirming the market’s growth prospects over the upcoming years.

Market Drivers

Several factors drive the global autologous cell therapy market. The following are the key drivers of the global autologous cell therapy market:

Increased Personalized Medicines Demand

One of the primary drivers of the global autologous cell therapy market is the increasing demand for personalized medicine. Autologous cell therapies are uniquely tailored to individual patients, using the patient’s cells, tissues, or biological materials. This level of personalization is particularly significant in cancer treatment, where therapies like CAR-T cell therapy are designed to target specific antigens on cancer cells, minimizing harm to healthy tissues and reducing side effects. Personalized treatments offer the potential for improved efficacy and address the growing preference for therapies that align with their genetic and medical profiles. This demand for personalized medicine drives investments, research, and clinical adoption of autologous cell therapies across various medical conditions.

The rising chronic disease prevalence and personalized medication demand will likely fuel market expansion over the forecast period. For example, the Food & Drug Administration (FDA) approved tisagenlecleucel (Kymriah) for individuals with certain forms of non-Hodgkin lymphoma in 2018, making it the second CAR T-cell therapy licensed for lymphoma. As a result, rising demand and adoption of personalized autologous cell treatments such as CAR-T are projected to propel market growth.

Market Restraints

The global autologous cell therapy market faces challenges that may hinder its growth. These include the following:

High Treatment Costs and Accessibility Barriers

One of the major restraints on the global autologous cell therapy market is the high cost associated with these treatments. Autologous cell therapies involve a complex and often labor-intensive process, including cell collection, isolation, expansion, modification, and reinfusion. Each process step requires specialized equipment and skilled personnel, contributing to substantial production costs. Additionally, the need for stringent quality control measures and regulatory compliance further adds to the expenses. Moreover, autologous cell therapies are often customized for individual patients, challenging economies of scale. Thus, these therapies can be prohibitively expensive for many patients, limiting their accessibility and affordability.

Opportunities

The global autologous cell therapy market offers significant growth opportunities. These include the following:

Emerging Therapeutic Modalities and Innovations

Continuous advancements in cell therapy technologies present a substantial opportunity for the autologous cell therapy market. Innovations in cell processing, gene editing, and manufacturing automation are enhancing the efficiency, scalability, and cost-effectiveness of producing personalized cell therapies. For example, the development of closed, automated systems for cell manufacturing minimizes contamination risks and reduces production costs. Furthermore, gene-editing tools like CRISPR-Cas9 enable precise and targeted modifications of patient-derived cells for therapeutic purposes, expanding the therapeutic potential of autologous cell therapies. These technological advancements improve the overall feasibility of these therapies and, attract investment, foster research, and encourage the development of novel treatments, ultimately promoting market growth.

Competitive Landscape

Key Players

The competitive landscape of the global autologous cell therapy market is characterized by intense rivalry among various industry players, including biotechnology companies, pharmaceutical firms, and academic research institutions. The following are some of the top market players and their market shares:

  • BrainStorm Cell Therapeutics
  • Pharmicell Co. Inc
  • Opexa Therapeutics
  • Caladrius Biosciences Inc
  • U.S. Stem Cell Inc
  • Lonza
  • Bristol Myers Squibb
  • Novartis
  • Tego Science
  • Corning Incorporated
  • Bio Elpida
  • Vericel Corporation
  • Catalent Inc
  • Sartorius AG
  • Others

These players are vying for market share and technological leadership by investing heavily in research & development efforts to advance cell therapy platforms and manufacturing processes. Strategic collaborations, mergers, and acquisitions are commonplace, allowing companies to broaden their product portfolios, enhance manufacturing capabilities, and access a wider patient base. Regulatory compliance, stringent quality control, and adherence to evolving standards are critical factors in gaining a competitive edge. Moreover, the market’s growth is fueled by the emergence of startups and smaller enterprises that bring innovation and novel therapeutic approaches, further intensifying competition in this dynamic and rapidly evolving sector.

In April 2022, TreeFrog Therapeutics announced The Stem Cell SpaceShot Grant, which will fund research in stem cell biology and regenerative medicine for USD 100,000.

In May 2020, Lonza and Noga Therapeutics teamed to develop autologous lentiviral gene therapy using the Cocoon Platform. This relationship assisted the company in bringing new autologous gene therapy for Primary Immune Deficiencies (PIDs) to the clinic and patients. This technique helped the corporation strengthen commercial relationships and expand its customer base.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Summary of Key Findings

  • The autologous cell therapy market is expected to grow robustly, driven by increasing demand for personalized medicine and advancements in cell therapy technologies.
  • Market segmented by cell type, application, end-user, source, and region.
  • Stem cell-based therapies, especially those using mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs), dominate the autologous cell therapy market due to their versatility and potential for personalized treatments.
  • Within the autologous cell therapy market, oncology applications, such as CAR-T cell therapies for lymphoma and leukemia, have gained significant traction and represent a substantial portion of the market.
  • The high cost associated with autologous cell therapy procedures, including cell isolation and manufacturing, remains a key barrier to wider adoption.
  • Ongoing advancements in manufacturing techniques, such as automation and scalable production processes, are streamlining the development and commercialization of autologous cell therapy products.
  • Integrating autologous cell therapy with digital health platforms allows for real-time monitoring of patient outcomes, treatment efficacy, and adherence to therapy protocols.

Future Outlook

  • Continued advancements in gene editing, cell expansion, and cryopreservation technologies are expected to improve the efficiency and scalability of autologous cell therapies.
  • Biobanking facilities that store and manage patient-derived cells are seeing growth to support the storage and retrieval of cells for autologous therapies.
  • Many clinical trials are ongoing worldwide, assessing the safety and efficacy of various autologous cell therapy approaches across different disease indications.
  • A shift toward patient-centric healthcare will fuel the adoption of autologous cell therapies, aligning treatments with individual genetic profiles.

Segmentation

  • By Cell Type
    • Mesenchymal Stem Cells
    • Chondrocytes
    • Dendritic Cells
    • Tumor-Infiltrating Lymphocytes
    • Others
  • By Application
    • Cancer Treatment
    • Autoimmune Diseases
    • Cardiovascular Diseases
    • Musculoskeletal Disorders
    • Neurological Disorders
    • Others
  • By End-User
    • Hospitals and Clinics
    • Research Institutes
    • Biotechnology and Pharmaceutical Companies
  • By Source
    • Bone Marrow
    • Blood
    • Adipose Tissue
    • Skin
    • Other Tissues
  • By Region
    • North America
      • The U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • The U.K.
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • South Korea
      • South-east Asia
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Argentina
      • Rest of Latin America
    • Middle East & Africa
      • GCC Countries
      • South Africa

Adjacent Markets

Several adjacent markets have high revenue growth opportunities in the autologous cell therapy market. The key adjacent markets for autologous cell therapy market –

1. Preface

1.1. Report Description

1.1.1. Purpose of the Report

1.1.2. Target Audience

1.1.3. USP and Key Offerings

1.2. Research Scope

1.3. Market Introduction

 

2. Executive Summary

2.1. Market Snapshot: Global Autologous Cell Therapy Market

2.1.1. Global Autologous Cell Therapy Market, By Cell Type

2.1.2. Global Autologous Cell Therapy Market, By Application

2.1.3. Global Autologous Cell Therapy Market, By End-User

2.1.4. Global Autologous Cell Therapy Market, By Source

2.1.5. Global Autologous Cell Therapy Market, By Region

2.2. Insights from Primary Respondents

 

3. Market Dynamics & Factors Analysis

3.1. Introduction

3.1.1. Global Autologous Cell Therapy Market Value, 2017-2030, (US$ Mn)

3.1.2. Y-o-Y Growth Trend Analysis

3.2. Market Dynamics

3.2.1. Autologous Cell Therapy Market Drivers

3.2.2. Autologous Cell Therapy Market Restraints

3.2.3. Autologous Cell Therapy Market Opportunities

3.2.4. Major Autologous Cell Therapy Industry Challenges

3.3. Growth and Development Patterns

3.4. Investment Feasibility Analysis

3.5. Market Opportunity Analysis

3.5.1. Cell Type

3.5.2. Application

3.5.3. End-User

3.5.4. Source

3.5.5. Geography

 

4. Market Competitive Landscape Analysis

4.1. Company Market Share Analysis, 2022

4.1.1. Global Autologous Cell Therapy Market: Company Market Share, Value 2022

4.1.2. Global Autologous Cell Therapy Market: Top 6 Company Market Share, Value 2022

4.1.3. Global Autologous Cell Therapy Market: Top 3 Company Market Share, Value 2022

4.2. Global Autologous Cell Therapy Market: Company Revenue Share Analysis, 2022

4.3. Company Assessment Metrics, 2022

4.3.1. Stars

4.3.2. Emerging Leaders

4.3.3. Pervasive Players

4.3.4. Participants

4.4. Startups/SMEs Assessment Metrics, 2022

4.4.1. Progressive Companies

4.4.2. Responsive Companies

4.4.3. Dynamic Companies

4.4.4. Starting Blocks

4.5. Strategic Development

4.5.1. Acquisition and Mergers

4.5.2. New Product Launch

4.5.3. Regional Expansion

4.5.4. Partnerships

4.6. Key Player Product Matrix

4.7. Potential for New Players in the Global Autologous Cell Therapy Market

 

5. Premium Insights

5.1. STAR (Situation, Task, Action, Results) Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Threat of New Entrants

5.2.2. Bargaining Power of Buyers/Consumers

5.2.3. Bargaining Power of Suppliers

5.2.4. Threat of Substitute Types

5.2.5. Intensity of Competitive Rivalry

5.3. PESTEL Analysis

5.3.1. Political Factors

5.3.2. Economic Factors

5.3.3. Social Factors

5.3.4. Technological Factors

5.3.5. Environmental Factors

5.3.6. Legal Factors

5.4. Key Market Trends

5.4.1. Demand Side Trends

5.4.2. Supply Side Trends

5.5. Value Chain Analysis

5.6. Technology Analysis

5.6.1. Research and development in the global market

5.6.2. Patent Analysis

5.6.3. Emerging technologies and their potential disruption to the market

5.7. Consumer Behaviour Analysis

5.7.1. Consumer Preferences and Expectations

5.7.2. Factors Influencing Consumer Buying Decisions

5.7.2.1. North America

5.7.2.2. Europe

5.7.2.3. Asia Pacific

5.7.2.4. Latin America

5.7.2.5. Middle East and Africa

5.7.3. Consumer Pain Points

5.8. Analysis and Recommendations

5.9. Adjacent Market Analysis

 

6. Market Positioning of Key Players, 2022

6.1. Company market share of key players, 2022

6.2. Competitive Benchmarking

6.3. Market Positioning of Key Vendors

6.4. Geographical Presence Analysis

6.5. Major Strategies Adopted by Key Players

6.5.1. Key Strategies Analysis

6.5.2. Mergers and Acquisitions

6.5.3. Partnerships

6.5.4. Product Launch

6.5.5. Geographical Expansion

6.5.6. Others

 

7. Impact Analysis of COVID-19 and Russia – Ukraine War on Autologous Cell Therapy Market

7.1. Ukraine-Russia War Impact

7.1.1. Uncertainty and Economic Instability

7.1.2. Supply chain disruptions

7.1.3. Regional market shifts

7.1.4. Shift in government priorities

7.2. COVID-19 Impact Analysis

7.2.1. Supply Chain Disruptions

7.2.2. Demand Fluctuations

7.2.3. Shift in Product Mix

7.2.4. Reduced Industrial Activity

7.2.5. Regional Impact Analysis

7.2.5.1. North America

7.2.5.2. Europe

7.2.5.3. Asia Pacific

7.2.5.4. Latin America

7.2.5.5. Middle East and Africa

 

8. Global Autologous Cell Therapy Market, By Cell Type

8.1. Global Autologous Cell Therapy Market Overview, by Cell Type

8.1.1. Global Autologous Cell Therapy Market Revenue Share, By Cell Type, 2022 Vs 2030 (in %)

8.2. Mesenchymal Stem Cells

8.2.1. Global Autologous Cell Therapy Market, By Mesenchymal Stem Cells, By Region, 2017-2030 (US$ Mn)

8.2.2. Market Dynamics for Mesenchymal Stem Cells

8.2.2.1. Drivers

8.2.2.2. Restraints

8.2.2.3. Opportunities

8.2.2.4. Trends

8.3. Chondrocytes

8.3.1. Global Autologous Cell Therapy Market, By Chondrocytes, By Region, 2017-2030 (US$ Mn)

8.3.2. Market Dynamics for Chondrocytes

8.3.2.1. Drivers

8.3.2.2. Restraints

8.3.2.3. Opportunities

8.3.2.4. Trends

8.4. Dendritic Cells

8.4.1. Global Autologous Cell Therapy Market, By Dendritic Cells, By Region, 2017-2030 (US$ Mn)

8.4.2. Market Dynamics for Dendritic Cells

8.4.2.1. Drivers

8.4.2.2. Restraints

8.4.2.3. Opportunities

8.4.2.4. Trends

8.5. Tumor-Infiltrating Lymphocytes

8.5.1. Global Autologous Cell Therapy Market, By Tumor-Infiltrating Lymphocytes, By Region, 2017-2030 (US$ Mn)

8.5.2. Market Dynamics for Tumor-Infiltrating Lymphocytes

8.5.2.1. Drivers

8.5.2.2. Restraints

8.5.2.3. Opportunities

8.5.2.4. Trends

8.6. Others

8.6.1. Global Autologous Cell Therapy Market, By Others, By Region, 2017-2030 (US$ Mn)

8.6.2. Market Dynamics for Others

8.6.2.1. Drivers

8.6.2.2. Restraints

8.6.2.3. Opportunities

8.6.2.4. Trends

 

9. Global Autologous Cell Therapy Market, By Application

9.1. Global Autologous Cell Therapy Market Overview, by Application

9.1.1. Global Autologous Cell Therapy Market Revenue Share, By Application, 2022 Vs 2030 (in %)

9.2. Cancer Treatment

9.2.1. Global Autologous Cell Therapy Market, By Cancer Treatment, By Region, 2017-2030 (US$ Mn)

9.2.2. Market Dynamics for Cancer Treatment

9.2.2.1. Drivers

9.2.2.2. Restraints

9.2.2.3. Opportunities

9.2.2.4. Trends

9.3. Autoimmune Diseases

9.3.1. Global Autologous Cell Therapy Market, By Autoimmune Diseases, By Region, 2017-2030 (US$ Mn)

9.3.2. Market Dynamics for Autoimmune Diseases

9.3.2.1. Drivers

9.3.2.2. Restraints

9.3.2.3. Opportunities

9.3.2.4. Trends

9.4. Cardiovascular Diseases

9.4.1. Global Autologous Cell Therapy Market, By Cardiovascular Diseases, By Region, 2017-2030 (US$ Mn)

9.4.2. Market Dynamics for Cardiovascular Diseases

9.4.2.1. Drivers

9.4.2.2. Restraints

9.4.2.3. Opportunities

9.4.2.4. Trends

9.5. Musculoskeletal Disorders

9.5.1. Global Autologous Cell Therapy Market, By Musculoskeletal Disorders, By Region, 2017-2030 (US$ Mn)

9.5.2. Market Dynamics for Musculoskeletal Disorders

9.5.2.1. Drivers

9.5.2.2. Restraints

9.5.2.3. Opportunities

9.5.2.4. Trends

9.6. Neurological Disorders

9.6.1. Global Autologous Cell Therapy Market, By Neurological Disorders, By Region, 2017-2030 (US$ Mn)

9.6.2. Market Dynamics for Neurological Disorders

9.6.2.1. Drivers

9.6.2.2. Restraints

9.6.2.3. Opportunities

9.6.2.4. Trends

9.7. Others

9.7.1. Global Autologous Cell Therapy Market, By Others, By Region, 2017-2030 (US$ Mn)

9.7.2. Market Dynamics for Others

9.7.2.1. Drivers

9.7.2.2. Restraints

9.7.2.3. Opportunities

9.7.2.4. Trends

 

10. Global Autologous Cell Therapy Market, By End-User

10.1. Global Autologous Cell Therapy Market Overview, by End-User

10.1.1. Global Autologous Cell Therapy Market Revenue Share, By End-User, 2022 Vs 2030 (in %)

10.2. Hospitals and Clinics

10.2.1. Global Autologous Cell Therapy Market, By Hospitals and Clinics, By Region, 2017-2030 (US$ Mn)

10.2.2. Market Dynamics for Hospitals and Clinics

10.2.2.1. Drivers

10.2.2.2. Restraints

10.2.2.3. Opportunities

10.2.2.4. Trends

10.3. Research Institutes

10.3.1. Global Autologous Cell Therapy Market, By Research Institutes, By Region, 2017-2030 (US$ Mn)

10.3.2. Market Dynamics for Research Institutes

10.3.2.1. Drivers

10.3.2.2. Restraints

10.3.2.3. Opportunities

10.3.2.4. Trends

10.4. Biotechnology and Pharmaceutical Companies

10.4.1. Global Autologous Cell Therapy Market, By Biotechnology and Pharmaceutical Companies, By Region, 2017-2030 (US$ Mn)

10.4.2. Market Dynamics for Biotechnology and Pharmaceutical Companies

10.4.2.1. Drivers

10.4.2.2. Restraints

10.4.2.3. Opportunities

10.4.2.4. Trends

 

11. Global Autologous Cell Therapy Market, By Source

11.1. Global Autologous Cell Therapy Market Overview, by Source

11.1.1. Global Autologous Cell Therapy Market Revenue Share, By Source, 2022 Vs 2030 (in %)

11.2. Bone Marrow

11.2.1. Global Autologous Cell Therapy Market, By Bone Marrow, By Region, 2017-2030 (US$ Mn)

11.2.2. Market Dynamics for Bone Marrow

11.2.2.1. Drivers

11.2.2.2. Restraints

11.2.2.3. Opportunities

11.2.2.4. Trends

11.3. Blood

11.3.1. Global Autologous Cell Therapy Market, By Blood, By Region, 2017-2030 (US$ Mn)

11.3.2. Market Dynamics for Blood

11.3.2.1. Drivers

11.3.2.2. Restraints

11.3.2.3. Opportunities

11.3.2.4. Trends

11.4. Adipose Tissue

11.4.1. Global Autologous Cell Therapy Market, By Adipose Tissue, By Region, 2017-2030 (US$ Mn)

11.4.2. Market Dynamics for Adipose Tissue

11.4.2.1. Drivers

11.4.2.2. Restraints

11.4.2.3. Opportunities

11.4.2.4. Trends

11.5. Skin

11.5.1. Global Autologous Cell Therapy Market, By Skin, By Region, 2017-2030 (US$ Mn)

11.5.2. Market Dynamics for Skin

11.5.2.1. Drivers

11.5.2.2. Restraints

11.5.2.3. Opportunities

11.5.2.4. Trends

11.6. Other Tissues

11.6.1. Global Autologous Cell Therapy Market, By Other Tissues, By Region, 2017-2030 (US$ Mn)

11.6.2. Market Dynamics for Other Tissues

11.6.2.1. Drivers

11.6.2.2. Restraints

11.6.2.3. Opportunities

11.6.2.4. Trends

 

12. Global Autologous Cell Therapy Market, By Region

12.1. Global Autologous Cell Therapy Market Overview, by Region

12.1.1. Global Autologous Cell Therapy Market, By Region, 2022 vs 2030 (in%)

12.2. Cell Type

12.2.1. Global Autologous Cell Therapy Market, By Cell Type, 2017-2030 (US$ Mn)

12.3. Application

12.3.1. Global Autologous Cell Therapy Market, By Application, 2017-2030 (US$ Mn)

12.4. End-User

12.4.1. Global Autologous Cell Therapy Market, By End-User, 2017-2030 (US$ Mn)

12.5. Source

12.5.1. Global Autologous Cell Therapy Market, By Source, 2017-2030 (US$ Mn)

 

13. North America Autologous Cell Therapy Market Analysis

13.1. Overview

13.1.1. Market Dynamics for North America

13.1.1.1. Drivers

13.1.1.2. Restraints

13.1.1.3. Opportunities

13.1.1.4. Trends

13.2. North America Autologous Cell Therapy Market, by Cell Type, 2017-2030(US$ Mn)

13.2.1. Overview

13.2.2. SRC Analysis

13.3. North America Autologous Cell Therapy Market, by Application, 2017-2030(US$ Mn)

13.3.1. Overview

13.3.2. SRC Analysis

13.4. North America Autologous Cell Therapy Market, by End-User, 2017-2030(US$ Mn)

13.4.1. Overview

13.4.2. SRC Analysis

13.5. North America Autologous Cell Therapy Market, by Source, 2017-2030(US$ Mn)

13.5.1. Overview

13.5.2. SRC Analysis

13.6. North America Autologous Cell Therapy Market, by Country, 2017-2030 (US$ Mn)

13.6.1. North America Autologous Cell Therapy Market, by Country, 2022 Vs 2030 (in%)

13.6.2. U.S.

13.6.3. Canada

13.6.4. Mexico

 

14. Europe Autologous Cell Therapy Market Analysis

14.1. Overview

14.1.1. Market Dynamics for North America

14.1.1.1. Drivers

14.1.1.2. Restraints

14.1.1.3. Opportunities

14.1.1.4. Trends

14.2. Europe Autologous Cell Therapy Market, by Cell Type, 2017-2030(US$ Mn)

14.2.1. Overview

14.2.2. SRC Analysis

14.3. Europe Autologous Cell Therapy Market, by Application, 2017-2030(US$ Mn)

14.3.1. Overview

14.3.2. SRC Analysis

14.4. Europe Autologous Cell Therapy Market, by End-User, 2017-2030(US$ Mn)

14.4.1. Overview

14.4.2. SRC Analysis

14.5. Europe Autologous Cell Therapy Market, by Source, 2017-2030(US$ Mn)

14.5.1. Overview

14.5.2. SRC Analysis

14.6. Europe Autologous Cell Therapy Market, by Country, 2017-2030 (US$ Mn)

14.6.1. Europe Autologous Cell Therapy Market, by Country, 2022 Vs 2030 (in%)

14.6.2. UK

14.6.3. France

14.6.4. Germany

14.6.5. Italy

14.6.6. Spain

14.6.7. Benelux

14.6.8. Russia

14.6.9. Rest of Europe

 

15. Asia Pacific Autologous Cell Therapy Market Analysis

15.1. Overview

15.1.1. Market Dynamics for North America

15.1.1.1. Drivers

15.1.1.2. Restraints

15.1.1.3. Opportunities

15.1.1.4. Trends

15.2. Asia Pacific Autologous Cell Therapy Market, by Cell Type, 2017-2030(US$ Mn)

15.2.1. Overview

15.2.2. SRC Analysis

15.3. Asia Pacific Autologous Cell Therapy Market, by Application, 2017-2030(US$ Mn)

15.3.1. Overview

15.3.2. SRC Analysis

15.4. Asia Pacific Autologous Cell Therapy Market, by End-User, 2017-2030(US$ Mn)

15.4.1. Overview

15.4.2. SRC Analysis

15.5. Asia Pacific Autologous Cell Therapy Market, by Source, 2017-2030(US$ Mn)

15.5.1. Overview

15.5.2. SRC Analysis

15.6. Asia Pacific Autologous Cell Therapy Market, by Country, 2017-2030 (US$ Mn)

15.6.1. Asia Pacific Autologous Cell Therapy Market, by Country, 2022 Vs 2030 (in%)

15.6.2. China

15.6.3. Japan

15.6.4. India

15.6.5. South Korea

15.6.6. South East Asia

15.6.7. Rest of Asia Pacific

 

16. Latin America Autologous Cell Therapy Market Analysis

16.1. Overview

16.1.1. Market Dynamics for North America

16.1.1.1. Drivers

16.1.1.2. Restraints

16.1.1.3. Opportunities

16.1.1.4. Trends

16.2. Latin America Autologous Cell Therapy Market, by Cell Type, 2017-2030(US$ Mn)

16.2.1. Overview

16.2.2. SRC Analysis

16.3. Latin America Autologous Cell Therapy Market, by Application, 2017-2030(US$ Mn)

16.3.1. Overview

16.3.2. SRC Analysis

16.4. Latin America Autologous Cell Therapy Market, by End-User, 2017-2030(US$ Mn)

16.4.1. Overview

16.4.2. SRC Analysis

16.5. Latin America Autologous Cell Therapy Market, by Source, 2017-2030(US$ Mn)

16.5.1. Overview

16.5.2. SRC Analysis

16.6. Latin America Autologous Cell Therapy Market, by Country, 2017-2030 (US$ Mn)

16.6.1. Latin America Autologous Cell Therapy Market, by Country, 2022 Vs 2030 (in%)

16.6.2. Brazil

16.6.3. Argentina

16.6.4. Rest of Latin America

 

17. Middle East Autologous Cell Therapy Market Analysis

17.1. Overview

17.1.1. Market Dynamics for North America

17.1.1.1. Drivers

17.1.1.2. Restraints

17.1.1.3. Opportunities

17.1.1.4. Trends

17.2. Middle East Autologous Cell Therapy Market, by Cell Type, 2017-2030(US$ Mn)

17.2.1. Overview

17.2.2. SRC Analysis

17.3. Middle East Autologous Cell Therapy Market, by Application, 2017-2030(US$ Mn)

17.3.1. Overview

17.3.2. SRC Analysis

17.4. Middle East Autologous Cell Therapy Market, by End-User, 2017-2030(US$ Mn)

17.4.1. Overview

17.4.2. SRC Analysis

17.5. Middle East Autologous Cell Therapy Market, by Source, 2017-2030(US$ Mn)

17.5.1. Overview

17.5.2. SRC Analysis

17.6. Middle East Autologous Cell Therapy Market, by Country, 2017-2030 (US$ Mn)

17.6.1. Middle East Autologous Cell Therapy Market, by Country, 2022 Vs 2030 (in%)

17.6.2. UAE

17.6.3. Saudi Arabia

17.6.4. Rest of Middle East

 

18. Africa Autologous Cell Therapy Market Analysis

18.1. Overview

18.1.1. Market Dynamics for North America

18.1.1.1. Drivers

18.1.1.2. Restraints

18.1.1.3. Opportunities

18.1.1.4. Trends

18.2. Africa Autologous Cell Therapy Market, by Cell Type, 2017-2030(US$ Mn)

18.2.1. Overview

18.2.2. SRC Analysis

18.3. Africa Autologous Cell Therapy Market, by Application, 2017-2030(US$ Mn)

18.3.1. Overview

18.3.2. SRC Analysis

18.4. Africa Autologous Cell Therapy Market, by End-User, 2017-2030(US$ Mn)

18.4.1. Overview

18.4.2. SRC Analysis

18.5. Africa Autologous Cell Therapy Market, by Source, 2017-2030(US$ Mn)

18.5.1. Overview

18.5.2. SRC Analysis

18.6. Africa Autologous Cell Therapy Market, by Country, 2017-2030 (US$ Mn)

18.6.1. Middle East Autologous Cell Therapy Market, by Country, 2022 Vs 2030 (in%)

18.6.2. South Africa

18.6.3. Egypt

18.6.4. Rest of Africa

 

19. Company Profiles

19.1. Brain Storm Cell Therapeutics

19.1.1. Company Overview

19.1.2. Products/Services Portfolio

19.1.3. Geographical Presence

19.1.4. SWOT Analysis

19.1.5. Financial Summary

19.1.5.1. Market Revenue and Net Profit (2019-2022)

19.1.5.2. Business Segment Revenue Analysis

19.1.5.3. Geographical Revenue Analysis

19.2. Pharmicell Co. Inc

19.3. Opexa Therapeutics

19.4. Caladrius Biosciences Inc

19.5. U.S. Stem Cell Inc

19.6. Lonza

19.7. Bristol Myers Squibb

19.8. Novartis

19.9. Tego Science

19.10. Corning Incorporated

19.11. Bio Elpida

19.12. Vericel Corporation

19.13. Catalent Inc

19.14. Sartorius AG

19.15. Others

 

20. Research Methodology

20.1. Research Methodology

20.2. Phase I – Secondary Research

20.3. Phase II – Data Modelling

20.3.1. Company Share Analysis Model

20.3.2. Revenue Based Modelling

20.4. Phase III – Primary Research

20.5. Research Limitations

20.5.1. Assumptions

 

List of Figures

FIG. 1 Global Autologous Cell Therapy Market: Research Methodology

FIG. 2 Market Size Estimation – Top Down & Bottom Up Approach

FIG. 3 Global Autologous Cell Therapy Market Segmentation

FIG. 4 Global Autologous Cell Therapy Market, by Cell Type, 2022 (US$ Mn)

FIG. 5 Global Autologous Cell Therapy Market, by Application, 2022 (US$ Mn)

FIG. 6 Global Autologous Cell Therapy Market, by End-User, 2022 (US$ Mn)

FIG. 7 Global Autologous Cell Therapy Market, by Source, 2022 (US$ Mn)

FIG. 8 Global Autologous Cell Therapy Market, by Geography, 2022 (US$ Mn)

FIG. 9 Attractive Investment Proposition, by Cell Type, 2022

FIG. 10 Attractive Investment Proposition, by Application, 2022

FIG. 11 Attractive Investment Proposition, by End-User, 2022

FIG. 12 Attractive Investment Proposition, by Source, 2022

FIG. 13 Attractive Investment Proposition, by Geography, 2022

FIG. 14 Global Market Share Analysis of Key Autologous Cell Therapy Market Manufacturers, 2022

FIG. 15 Global Market Positioning of Key Autologous Cell Therapy Market Manufacturers, 2022

FIG. 16 Global Autologous Cell Therapy Market Value Contribution, By Cell Type, 2022 & 2030 (Value %)

FIG. 17 Global Autologous Cell Therapy Market, by Mesenchymal Stem Cells, Value, 2017-2030 (US$ Mn)

FIG. 18 Global Autologous Cell Therapy Market, by Chondrocytes, Value, 2017-2030 (US$ Mn)

FIG. 19 Global Autologous Cell Therapy Market, by Dendritic Cells, Value, 2017-2030 (US$ Mn)

FIG. 20 Global Autologous Cell Therapy Market, by Tumor-Infiltrating Lymphocytes, Value, 2017-2030 (US$ Mn)

FIG. 21 Global Autologous Cell Therapy Market, by Others, Value, 2017-2030 (US$ Mn)

FIG. 22 Global Autologous Cell Therapy Market Value Contribution, By Application, 2022 & 2030 (Value %)

FIG. 23 Global Autologous Cell Therapy Market, by Cancer Treatment, Value, 2017-2030 (US$ Mn)

FIG. 24 Global Autologous Cell Therapy Market, by Autoimmune Diseases, Value, 2017-2030 (US$ Mn)

FIG. 25 Global Autologous Cell Therapy Market, by Cardiovascular Diseases, Value, 2017-2030 (US$ Mn)

FIG. 26 Global Autologous Cell Therapy Market, by Musculoskeletal Disorders, Value, 2017-2030 (US$ Mn)

FIG. 27 Global Autologous Cell Therapy Market, by Neurological Disorders, Value, 2017-2030 (US$ Mn)

FIG. 28 Global Autologous Cell Therapy Market, by Others, Value, 2017-2030 (US$ Mn)

FIG. 29 Global Autologous Cell Therapy Market Value Contribution, By End-User, 2022 & 2030 (Value %)

FIG. 30 Global Autologous Cell Therapy Market, by Hospitals and Clinics, Value, 2017-2030 (US$ Mn)

FIG. 31 Global Autologous Cell Therapy Market, by Research Institutes, Value, 2017-2030 (US$ Mn)

FIG. 32 Global Autologous Cell Therapy Market, by Biotechnology and Pharmaceutical Companies, Value, 2017-2030 (US$ Mn)

FIG. 33 Global Autologous Cell Therapy Market Value Contribution, By Source, 2022 & 2030 (Value %)

FIG. 34 Global Autologous Cell Therapy Market, by Bone Marrow, Value, 2017-2030 (US$ Mn)

FIG. 35 Global Autologous Cell Therapy Market, by Blood, Value, 2017-2030 (US$ Mn)

FIG. 36 Global Autologous Cell Therapy Market, by Adipose Tissue, Value, 2017-2030 (US$ Mn)

FIG. 37 Global Autologous Cell Therapy Market, by Skin, Value, 2017-2030 (US$ Mn)

FIG. 38 Global Autologous Cell Therapy Market, by Other Tissues, Value, 2017-2030 (US$ Mn)

FIG. 39 North America Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 40 U.S. Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 41 Canada Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 42 Mexico Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 43 Europe Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 44 Germany Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 45 France Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 46 U.K. Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 47 Italy Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 48 Spain Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 49 Benelux Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 50 Russia Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 51 Rest of Europe Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 52 Asia Pacific Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 53 China Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 54 Japan Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 55 India Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 56 South Korea Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 57 South-East Asia Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 58 Rest of Asia Pacific Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 59 Latin America Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 60 Brazil Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 61 Argentina Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 62 Rest of Latin America Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 63 Middle East Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 64 UAE Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 65 Saudi Arabia Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 66 Rest of Middle East Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 67 Africa Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 68 South Africa Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 69 Egypt Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

FIG. 70 Rest of Africa Autologous Cell Therapy Market, 2017-2030 (US$ Mn)

 

List of Tables

TABLE 1 Market Snapshot: Global Autologous Cell Therapy Market

TABLE 2 Global Autologous Cell Therapy Market: Market Drivers Impact Analysis

TABLE 3 Global Autologous Cell Therapy Market: Market Restraints Impact Analysis

TABLE 4 Global Autologous Cell Therapy Market, by Competitive Benchmarking, 2022

TABLE 5 Global Autologous Cell Therapy Market, by Geographical Presence Analysis, 2022

TABLE 6 Global Autologous Cell Therapy Market, by Key Strategies Analysis, 2022

TABLE 7 Global Autologous Cell Therapy Market, by Mesenchymal Stem Cells, By Region, 2017-2022 (US$ Mn)

TABLE 8 Global Autologous Cell Therapy Market, by Mesenchymal Stem Cells, By Region, 2023-2030 (US$ Mn)

TABLE 9 Global Autologous Cell Therapy Market, by Chondrocytes, By Region, 2017-2022 (US$ Mn)

TABLE 10 Global Autologous Cell Therapy Market, by Chondrocytes, By Region, 2023-2030 (US$ Mn)

TABLE 11 Global Autologous Cell Therapy Market, by Dendritic Cells, By Region, 2017-2022 (US$ Mn)

TABLE 12 Global Autologous Cell Therapy Market, by Dendritic Cells, By Region, 2023-2030 (US$ Mn)

TABLE 13 Global Autologous Cell Therapy Market, by Tumor-Infiltrating Lymphocytes, By Region, 2017-2022 (US$ Mn)

TABLE 14 Global Autologous Cell Therapy Market, by Tumor-Infiltrating Lymphocytes, By Region, 2023-2030 (US$ Mn)

TABLE 15 Global Autologous Cell Therapy Market, by Others, By Region, 2017-2022 (US$ Mn)

TABLE 16 Global Autologous Cell Therapy Market, by Others, By Region, 2023-2030 (US$ Mn)

TABLE 17 Global Autologous Cell Therapy Market, by Cancer Treatment, By Region, 2017-2022 (US$ Mn)

TABLE 18 Global Autologous Cell Therapy Market, by Cancer Treatment, By Region, 2023-2030 (US$ Mn)

TABLE 19 Global Autologous Cell Therapy Market, by Autoimmune Diseases, By Region, 2017-2022 (US$ Mn)

TABLE 20 Global Autologous Cell Therapy Market, by Autoimmune Diseases, By Region, 2023-2030 (US$ Mn)

TABLE 21 Global Autologous Cell Therapy Market, by Cardiovascular Diseases, By Region, 2017-2022 (US$ Mn)

TABLE 22 Global Autologous Cell Therapy Market, by Cardiovascular Diseases, By Region, 2023-2030 (US$ Mn)

TABLE 23 Global Autologous Cell Therapy Market, by Musculoskeletal Disorders, By Region, 2017-2022 (US$ Mn)

TABLE 24 Global Autologous Cell Therapy Market, by Musculoskeletal Disorders, By Region, 2023-2030 (US$ Mn)

TABLE 25 Global Autologous Cell Therapy Market, by Neurological Disorders, By Region, 2017-2022 (US$ Mn)

TABLE 26 Global Autologous Cell Therapy Market, by Neurological Disorders, By Region, 2023-2030 (US$ Mn)

TABLE 27 Global Autologous Cell Therapy Market, by Others, By Region, 2017-2022 (US$ Mn)

TABLE 28 Global Autologous Cell Therapy Market, by Others, By Region, 2023-2030 (US$ Mn)

TABLE 29 Global Autologous Cell Therapy Market, by Hospitals and Clinics, By Region, 2017-2022 (US$ Mn)

TABLE 30 Global Autologous Cell Therapy Market, by Hospitals and Clinics, By Region, 2023-2030 (US$ Mn)

TABLE 31 Global Autologous Cell Therapy Market, by Research Institutes, By Region, 2017-2022 (US$ Mn)

TABLE 32 Global Autologous Cell Therapy Market, by Research Institutes, By Region, 2023-2030 (US$ Mn)

TABLE 33 Global Autologous Cell Therapy Market, by Biotechnology and Pharmaceutical Companies, By Region, 2017-2022 (US$ Mn)

TABLE 34 Global Autologous Cell Therapy Market, by Biotechnology and Pharmaceutical Companies, By Region, 2023-2030 (US$ Mn)

TABLE 35 Global Autologous Cell Therapy Market, by Bone Marrow, By Region, 2017-2022 (US$ Mn)

TABLE 36 Global Autologous Cell Therapy Market, by Bone Marrow, By Region, 2023-2030 (US$ Mn)

TABLE 37 Global Autologous Cell Therapy Market, by Blood, By Region, 2017-2022 (US$ Mn)

TABLE 38 Global Autologous Cell Therapy Market, by Blood, By Region, 2023-2030 (US$ Mn)

TABLE 39 Global Autologous Cell Therapy Market, by Adipose Tissue, By Region, 2017-2022 (US$ Mn)

TABLE 40 Global Autologous Cell Therapy Market, by Adipose Tissue, By Region, 2023-2030 (US$ Mn)

TABLE 41 Global Autologous Cell Therapy Market, by Skin, By Region, 2017-2022 (US$ Mn)

TABLE 42 Global Autologous Cell Therapy Market, by Skin, By Region, 2023-2030 (US$ Mn)

TABLE 43 Global Autologous Cell Therapy Market, by Other Tissues, By Region, 2017-2022 (US$ Mn)

TABLE 44 Global Autologous Cell Therapy Market, by Other Tissues, By Region, 2023-2030 (US$ Mn)

TABLE 45 Global Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 46 Global Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 47 Global Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 48 Global Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 49 Global Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 50 Global Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 51 Global Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 52 Global Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 53 Global Autologous Cell Therapy Market, by Region, 2017-2022 (US$ Mn)

TABLE 54 Global Autologous Cell Therapy Market, by Region, 2023-2030 (US$ Mn)

TABLE 55 North America Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 56 North America Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 57 North America Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 58 North America Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 59 North America Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 60 North America Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 61 North America Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 62 North America Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 63 North America Autologous Cell Therapy Market, by Country, 2017-2022 (US$ Mn)

TABLE 64 North America Autologous Cell Therapy Market, by Country, 2023-2030 (US$ Mn)

TABLE 65 United States Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 66 United States Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 67 United States Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 68 United States Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 69 United States Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 70 United States Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 71 United States Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 72 United States Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 73 Canada Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 74 Canada Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 75 Canada Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 76 Canada Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 77 Canada Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 78 Canada Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 79 Canada Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 80 Canada Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 81 Mexico Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 82 Mexico Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 83 Mexico Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 84 Mexico Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 85 Mexico Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 86 Mexico Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 87 Mexico Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 88 Mexico Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 89 Europe Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 90 Europe Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 91 Europe Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 92 Europe Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 93 Europe Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 94 Europe Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 95 Europe Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 96 Europe Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 97 Europe Autologous Cell Therapy Market, by Country, 2017-2022 (US$ Mn)

TABLE 98 Europe Autologous Cell Therapy Market, by Country, 2023-2030 (US$ Mn)

TABLE 99 Germany Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 100 Germany Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 101 Germany Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 102 Germany Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 103 Germany Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 104 Germany Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 105 Germany Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 106 Germany Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 107 France Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 108 France Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 109 France Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 110 France Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 111 France Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 112 France Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 113 France Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 114 France Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 115 United Kingdom Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 116 United Kingdom Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 117 United Kingdom Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 118 United Kingdom Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 119 United Kingdom Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 120 United Kingdom Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 121 United Kingdom Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 122 United Kingdom Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 123 Italy Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 124 Italy Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 125 Italy Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 126 Italy Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 127 Italy Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 128 Italy Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 129 Italy Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 130 Italy Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 131 Spain Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 132 Spain Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 133 Spain Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 134 Spain Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 135 Spain Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 136 Spain Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 137 Spain Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 138 Spain Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 139 Benelux Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 140 Benelux Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 141 Benelux Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 142 Benelux Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 143 Benelux Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 144 Benelux Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 145 Benelux Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 146 Benelux Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 147 Russia Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 148 Russia Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 149 Russia Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 150 Russia Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 151 Russia Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 152 Russia Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 153 Russia Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 154 Russia Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 155 Rest of Europe Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 156 Rest of Europe Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 157 Rest of Europe Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 158 Rest of Europe Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 159 Rest of Europe Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 160 Rest of Europe Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 161 Rest of Europe Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 162 Rest of Europe Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 163 Asia Pacific Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 164 Asia Pacific Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 165 Asia Pacific Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 166 Asia Pacific Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 167 Asia Pacific Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 168 Asia Pacific Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 169 Asia Pacific Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 170 Asia Pacific Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 171 China Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 172 China Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 173 China Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 174 China Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 175 China Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 176 China Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 177 China Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 178 China Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 179 Japan Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 180 Japan Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 181 Japan Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 182 Japan Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 183 Japan Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 184 Japan Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 185 Japan Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 186 Japan Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 187 India Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 188 India Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 189 India Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 190 India Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 191 India Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 192 India Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 193 India Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 194 India Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 195 South Korea Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 196 South Korea Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 197 South Korea Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 198 South Korea Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 199 South Korea Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 200 South Korea Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 201 South Korea Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 202 South Korea Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 203 South-East Asia Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 204 South-East Asia Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 205 South-East Asia Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 206 South-East Asia Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 207 South-East Asia Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 208 South-East Asia Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 209 South-East Asia Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 210 South-East Asia Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 211 Rest of Asia Pacific Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 212 Rest of Asia Pacific Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 213 Rest of Asia Pacific Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 214 Rest of Asia Pacific Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 215 Rest of Asia Pacific Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 216 Rest of Asia Pacific Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 217 Rest of Asia Pacific Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 218 Rest of Asia Pacific Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 219 Latin America Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 220 Latin America Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 221 Latin America Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 222 Latin America Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 223 Latin America Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 224 Latin America Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 225 Latin America Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 226 Latin America Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 227 Brazil Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 228 Brazil Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 229 Brazil Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 230 Brazil Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 231 Brazil Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 232 Brazil Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 233 Brazil Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 234 Brazil Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 235 Argentina Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 236 Argentina Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 237 Argentina Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 238 Argentina Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 239 Argentina Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 240 Argentina Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 241 Argentina Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 242 Argentina Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 243 Rest of Latin America Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 244 Rest of Latin America Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 245 Rest of Latin America Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 246 Rest of Latin America Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 247 Rest of Latin America Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 248 Rest of Latin America Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 249 Rest of Latin America Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 250 Rest of Latin America Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 251 Middle East Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 252 Middle East Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 253 Middle East Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 254 Middle East Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 255 Middle East Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 256 Middle East Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 257 Middle East Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 258 Middle East Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 259 UAE Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 260 UAE Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 261 UAE Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 262 UAE Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 263 UAE Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 264 UAE Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 265 UAE Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 266 UAE Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 267 Saudi Arabia Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 268 Saudi Arabia Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 269 Saudi Arabia Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 270 Saudi Arabia Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 271 Saudi Arabia Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 272 Saudi Arabia Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 273 Saudi Arabia Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 274 Saudi Arabia Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 275 Rest of Middle East Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 276 Rest of Middle East Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 277 Rest of Middle East Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 278 Rest of Middle East Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 279 Rest of Middle East Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 280 Rest of Middle East Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 281 Rest of Middle East Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 282 Rest of Middle East Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 283 Africa Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 284 Africa Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 285 Africa Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 286 Africa Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 287 Africa Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 288 Africa Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 289 Africa Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 290 Africa Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 291 South Africa Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 292 South Africa Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 293 South Africa Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 294 South Africa Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 295 South Africa Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 296 South Africa Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 297 South Africa Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 298 South Africa Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 299 Egypt Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 300 Egypt Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 301 Egypt Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 302 Egypt Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 303 Egypt Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 304 Egypt Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 305 Egypt Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 306 Egypt Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn)

TABLE 307 Rest of Africa Autologous Cell Therapy Market, by Cell Type, 2017-2022 (US$ Mn)

TABLE 308 Rest of Africa Autologous Cell Therapy Market, by Cell Type, 2023-2030 (US$ Mn)

TABLE 309 Rest of Africa Autologous Cell Therapy Market, by Application, 2017-2022 (US$ Mn)

TABLE 310 Rest of Africa Autologous Cell Therapy Market, by Application, 2023-2030 (US$ Mn)

TABLE 311 Rest of Africa Autologous Cell Therapy Market, by End-User, 2017-2022 (US$ Mn)

TABLE 312 Rest of Africa Autologous Cell Therapy Market, by End-User, 2023-2030 (US$ Mn)

TABLE 313 Rest of Africa Autologous Cell Therapy Market, by Source, 2017-2022 (US$ Mn)

TABLE 314 Rest of Africa Autologous Cell Therapy Market, by Source, 2023-2030 (US$ Mn

Frequently Asked Questions

What is the current size of the global autologous cell therapy market?

The global autologous cell therapy market was valued at USD 4518.9 Million in 2022.

What is the expected growth rate of the autologous cell therapy market between 2023 and 2030?

The autologous cell therapy market is expected to grow at a CAGR of 22.3% between 2023 and 2030, reaching USD 22617.48 Million in 2030.

Which segment is leading the market share in terms of cell type?

Mesenchymal stem cells are the leading segment by cell type, holding over 30% share in value in 2022.

Which application segment governs the global demand for autologous cell therapy?

The cancer treatment segment governs the global demand for autologous cell therapy, holding a massive share of over 28% in 2022.

Which end-user segment will post the highest CAGR in the forecast period?

The research institutes segment will post the highest CAGR over the projection period.

Which region is fueling the growth of the autologous cell therapy industry?

North America contributes to the robust growth of the autologous cell therapy industry, with over one-third of its market share in 2022.

Who are the major players in the global autologous cell therapy market?

The top players include BrainStorm Cell Therapeutics, Pharmicell Co. Inc, Opexa Therapeutics, Caladrius Biosciences Inc, U.S. Stem Cell Inc, Lonza, Bristol Myers Squibb, Novartis, Tego Science, Corning Incorporated, Bio Elpida, Vericel Corporation, Catalent Inc, Sartorius AG, and Others.

What are the major market drivers of the autologous cell therapy industry?

The major market drivers are the increased demand for personalized medicine and continuous technological advancements.

What are the major market restraints of the autologous cell therapy industry?

The major market restraints are the high treatment costs, regulatory challenges, and approval delays.

What are the major market opportunities of the autologous cell therapy industry?

The major market opportunities of the autologous cell therapy industry involve expanding therapeutic applications and leveraging technological advancements to improve efficiency and scalability.

UAE Minimally Invasive Biopsy Techniques Market

Published:
Report ID: 38790

Saudi Arabia Minimally Invasive Biopsy Technique Market

Published:
Report ID: 38766

Lung Cancer Therapeutics Market

Published:
Report ID: 38769

Breast Cancer Market

Published:
Report ID: 38761

Positive Patient Identification (PPID) Market

Published:
Report ID: 10622

Inflation Devices Market

Published:
Report ID: 38697

Microbiology Culture Market

Published:
Report ID: 38672

Medical Processing Seals Market

Published:
Report ID: 38667

Egypt In-Vitro Fertilization (IVF) Market

Published:
Report ID: 38526

Middle East Lab Titration Devices Market

Published:
Report ID: 38542

Tattoo Needles Market

Published:
Report ID: 10912

Australia In Vitro Diagnostics (IVD) Market

Published:
Report ID: 38375

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN